Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition
Anti-neoplastic agents for cancer treatment utilize many different mechanisms of action and, when combined, can result in potent inhibition of cancer growth. Combination therapies can result in long-term, durable remission or even cure; however, too many times, these anti-neoplastic agents lose thei...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/5/4722 |
| _version_ | 1797615179692769280 |
|---|---|
| author | Sunanda Singh Hector J. Gomez Shreya Thakkar Samara P. Singh Ashutosh S. Parihar |
| author_facet | Sunanda Singh Hector J. Gomez Shreya Thakkar Samara P. Singh Ashutosh S. Parihar |
| author_sort | Sunanda Singh |
| collection | DOAJ |
| description | Anti-neoplastic agents for cancer treatment utilize many different mechanisms of action and, when combined, can result in potent inhibition of cancer growth. Combination therapies can result in long-term, durable remission or even cure; however, too many times, these anti-neoplastic agents lose their efficacy due to the development of acquired drug resistance (ADR). In this review, we evaluate the scientific and medical literature that elucidate STAT3-mediated mechanisms of resistance to cancer therapeutics. Herein, we have found that at least 24 different anti-neoplastic agents—standard toxic chemotherapeutic agents, targeted kinase inhibitors, anti-hormonal agents, and monoclonal antibodies—that utilize the STAT3 signaling pathway as one mechanism of developing therapeutic resistance. Targeting STAT3, in combination with existing anti-neoplastic agents, may prove to be a successful therapeutic strategy to either prevent or even overcome ADR to standard and novel cancer therapies. |
| first_indexed | 2024-03-11T07:22:50Z |
| format | Article |
| id | doaj.art-a07972be5b49404b8d2367bea94153ae |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T07:22:50Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-a07972be5b49404b8d2367bea94153ae2023-11-17T07:52:41ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-03-01245472210.3390/ijms24054722Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 InhibitionSunanda Singh0Hector J. Gomez1Shreya Thakkar2Samara P. Singh3Ashutosh S. Parihar4Singh Biotechnology, 1547 Fox Grape Loop, Lutz, FL 33558, USASingh Biotechnology, 1547 Fox Grape Loop, Lutz, FL 33558, USADepartment of Cell Biology, Microbiology and Molecular Biology, University of South Florida, Tampa, FL 33620, USADepartment of Surgery, Division of Surgical Oncology, University of Miami Miller School of Medicine, Miami, FL 33136, USASingh Biotechnology, 1547 Fox Grape Loop, Lutz, FL 33558, USAAnti-neoplastic agents for cancer treatment utilize many different mechanisms of action and, when combined, can result in potent inhibition of cancer growth. Combination therapies can result in long-term, durable remission or even cure; however, too many times, these anti-neoplastic agents lose their efficacy due to the development of acquired drug resistance (ADR). In this review, we evaluate the scientific and medical literature that elucidate STAT3-mediated mechanisms of resistance to cancer therapeutics. Herein, we have found that at least 24 different anti-neoplastic agents—standard toxic chemotherapeutic agents, targeted kinase inhibitors, anti-hormonal agents, and monoclonal antibodies—that utilize the STAT3 signaling pathway as one mechanism of developing therapeutic resistance. Targeting STAT3, in combination with existing anti-neoplastic agents, may prove to be a successful therapeutic strategy to either prevent or even overcome ADR to standard and novel cancer therapies.https://www.mdpi.com/1422-0067/24/5/4722STAT3acquired drug resistancekinase inhibitorschemotherapymonoclonal antibodiesimmune checkpoint inhibition |
| spellingShingle | Sunanda Singh Hector J. Gomez Shreya Thakkar Samara P. Singh Ashutosh S. Parihar Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition International Journal of Molecular Sciences STAT3 acquired drug resistance kinase inhibitors chemotherapy monoclonal antibodies immune checkpoint inhibition |
| title | Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition |
| title_full | Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition |
| title_fullStr | Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition |
| title_full_unstemmed | Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition |
| title_short | Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition |
| title_sort | overcoming acquired drug resistance to cancer therapies through targeted stat3 inhibition |
| topic | STAT3 acquired drug resistance kinase inhibitors chemotherapy monoclonal antibodies immune checkpoint inhibition |
| url | https://www.mdpi.com/1422-0067/24/5/4722 |
| work_keys_str_mv | AT sunandasingh overcomingacquireddrugresistancetocancertherapiesthroughtargetedstat3inhibition AT hectorjgomez overcomingacquireddrugresistancetocancertherapiesthroughtargetedstat3inhibition AT shreyathakkar overcomingacquireddrugresistancetocancertherapiesthroughtargetedstat3inhibition AT samarapsingh overcomingacquireddrugresistancetocancertherapiesthroughtargetedstat3inhibition AT ashutoshsparihar overcomingacquireddrugresistancetocancertherapiesthroughtargetedstat3inhibition |